In this town, carved into the Appalachian mountains, in a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach. Over the past year, only 3 percent of the state’s Medicaid beneficiaries with the disease received treatment

Quick Read

Request for life-saving anti-viral medication rejected on technicality. Judge finds Pennsylvania protocol for inmates out of line with constitution

Quick Read

Two Washington state insurers — Group Health Cooperative and BridgeSpan — are targeted in class-action lawsuits that claim the companies are unfairly rationing new drugs that can cure hepatitis C based on high cost, not medical need

Quick Read

Public anger at drug companies is “an abomination,” Ron Cohen, chairman of the big industry group BIO, said at the Biotech Showcase. All the talk about pharma profiteering, Cohen said, is “a perversion of reality.”

Quick Read

All told, 33 states spent more than $1 billion to treat the disease with Gilead Sciences’ Sovaldi, according to data released Tuesday by Sens. Charles Grassley, R-Iowa, and Ron Wyden, D-Ore.

Quick Read

Treating Hep C isn’t cheap, but experts say it’s cost-effective

Quick Read

Researchers at the University of Pennsylvania Perelman School of Medicine analyzed the hepatitis C prescriptions from 2,342 patients in Maryland, Delaware, Pennsylvania and New Jersey that were submitted between November 2014 and April 2015 to a large specialty pharmacy that serves the region

Quick Read

No Easy Feat

July 30, 2015

Promoting the PrEP pill for HIV prevention among Latinos. “It hasn’t really hit the Latino community yet,” Jesse Hinostroza, an HIV prevention specialist with AltaMed health clinics, said while sitting at a table with a bowl of condoms and a stack of bilingual pamphlets about the pill. “They aren’t educated about it”

Quick Read